The global healthcare technology (HealthTech) mergers and acquisitions (M&A) ecosystem at mid-year 2026 has entered a period described by corporate development executives and private equity sponsors as "HealthTech 2.0" or "Industrial Maturity". Moving decisively beyond the venture-subsidised experimentation of the early 2020s and the severe valuation recalibrations of 2022–2023, the current transaction environment demonstrates strong capital deployment alongside target select

The European healthcare technology and medical technology (MedTech) landscape entering 2026 stands at a profound inflection point, characterised by a transition from the speculative fragmentation of the early 2020s to a disciplined era of "industrial maturity". Following a period of post-pandemic recalibration in 2024 and a tentative recovery in 2025, the market is poised for a robust, albeit structurally transformed, resurgence in capital deployment and mergers and acquisiti